KRYS

SEC source: 0001801385-26-000002 · wk-form4_1772580832.xml · nonDerivative · entry 2

ROMANO KATHRYN · CIK 0001801385 · Chief Accounting Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 22,806

F2 · shares: Represents the number of shares of common stock surrendered to the Company for tax withholding upon the vesting of 7,500 RSUs on February 27, 2026.

F3 · price: The closing price on February 27, 2026 of the Company's common stock on the Nasdaq Global Select Market.

SEC source: 0001801385-26-000002 · wk-form4_1772580832.xml · nonDerivative · entry 1

ROMANO KATHRYN · CIK 0001801385 · Chief Accounting Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 26,068

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: 15,000 performance stock units ("PSUs") were granted on February 29, 2024. Each PSU represented a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31 2024, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement. The PSUs vested ratably over a two-year period. All of the performance criteria were achieved and the remaining one-half of the PSUs granted, or 7,500 PSUs, vested on February 27, 2026.

SEC source: 0001298711-26-000002 · wk-form4_1772580780.xml · derivative · entry 17

Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 43,536

Underlying: Common Stock · 43,536 shares

Expires not disclosed

F18 · derivative.exercise_price: Each PSU represents a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the three year performance period, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on the vesting date.

F19 · shares: The number of PSUs in this column represents the number of shares of common stock the Reporting Person will receive assuming achievement of all of the performance criteria set by the Company's Compensation Committee for this PSU award and full vesting of this PSU award.

F20 · derivative.exercise_date: If any applicable portion of the performance criteria have been achieved, the PSU award shall cliff vest on February 27, 2029.

F21 · derivative.expiration_date: If some or all of the performance criteria are not achieved, the applicable portion of the PSU award will be forfeited.

SEC source: 0001298711-26-000002 · wk-form4_1772580780.xml · derivative · entry 16

Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,256

Underlying: Common Stock · 7,256 shares

Expires not disclosed

F16 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's continued service to the Company on each applicable vesting date.

F17 · derivative.exercise_date: The RSUs vest in four equal annual installments with the first installment vesting on February 27, 2027.

F17 · derivative.expiration_date: The RSUs vest in four equal annual installments with the first installment vesting on February 27, 2027.

SEC source: 0001298711-26-000002 · wk-form4_1772580780.xml · derivative · entry 15

Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,100

Underlying: Common Stock · 18,100 shares

Expires 2036-02-26

F15 · derivative.exercise_date: The stock options vest in four equal annual installments beginning on February 27, 2027.

SEC source: 0001298711-26-000002 · wk-form4_1772580780.xml · derivative · entry 14

Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,000

Underlying: Common Stock · 4,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: 16,000 restricted stock units ("RSUs") were granted on February 28, 2025. Each RSU represents a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's continued service to the Company on each applicable vesting date. The RSUs vest ratably over a four-year period with the first installment, or 4,000 RSUs, vesting on February 27, 2026.

F4 · derivative.exercise_date: 16,000 restricted stock units ("RSUs") were granted on February 28, 2025. Each RSU represents a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's continued service to the Company on each applicable vesting date. The RSUs vest ratably over a four-year period with the first installment, or 4,000 RSUs, vesting on February 27, 2026.

F4 · derivative.expiration_date: 16,000 restricted stock units ("RSUs") were granted on February 28, 2025. Each RSU represents a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's continued service to the Company on each applicable vesting date. The RSUs vest ratably over a four-year period with the first installment, or 4,000 RSUs, vesting on February 27, 2026.

SEC source: 0001298711-26-000002 · wk-form4_1772580780.xml · derivative · entry 13

Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 22,500 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: 45,000 performance stock units ("PSUs") were granted on February 29, 2024. Each PSU represented a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31, 2024, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement. The PSUs vested ratably over a two-year period. All of the performance criteria were achieved and the remaining one-half of the PSUs granted, or 22,500 PSUs, vested on February 27, 2026.

F1 · derivative.exercise_date: 45,000 performance stock units ("PSUs") were granted on February 29, 2024. Each PSU represented a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31, 2024, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement. The PSUs vested ratably over a two-year period. All of the performance criteria were achieved and the remaining one-half of the PSUs granted, or 22,500 PSUs, vested on February 27, 2026.

F1 · derivative.expiration_date: 45,000 performance stock units ("PSUs") were granted on February 29, 2024. Each PSU represented a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31, 2024, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement. The PSUs vested ratably over a two-year period. All of the performance criteria were achieved and the remaining one-half of the PSUs granted, or 22,500 PSUs, vested on February 27, 2026.

SEC source: 0001298711-26-000002 · wk-form4_1772580780.xml · nonDerivative · entry 10

Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Spouse

Disclosed balance after: 1,500,253

F7 · shares: These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Krish S. Krishnan.

F13 · shares: Represents number of shares of common stock surrendered to the Company for tax withholding by the Reporting Person's spouse, Krish S. Krishnan, upon the vesting of 5,725 RSUs on February 27, 2026.

F3 · price: The closing price on February 27, 2026 of the Company's common stock on the Nasdaq Global Select Market.

F8 · ownership.nature: Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person.

SEC source: 0001298711-26-000002 · wk-form4_1772580780.xml · nonDerivative · entry 9

Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Spouse

Disclosed balance after: 1,502,858

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · shares: These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Krish S. Krishnan.

F12 · shares: 22,900 restricted stock units ("RSUs") were granted on February 28, 2025, to the Reporting Person's spouse, Krish S. Krishnan. Each RSU represents a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's spouse continued service to the Company on each applicable vesting date. The RSUs vest ratably over a four-year period with the first installment, or 5,725 RSUs, vesting on February 27, 2026.

F8 · ownership.nature: Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person.

SEC source: 0001298711-26-000002 · wk-form4_1772580780.xml · nonDerivative · entry 8

Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Spouse

Disclosed balance after: 1,497,133

F7 · shares: These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Krish S. Krishnan.

F11 · shares: Represents number of shares of common stock surrendered to the Company for tax withholding by the Reporting Person's spouse, Krish S. Krishnan, upon the vesting of 26,250 PSUs on February 27, 2026.

F3 · price: The closing price on February 27, 2026 of the Company's common stock on the Nasdaq Global Select Market.

F8 · ownership.nature: Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person.

SEC source: 0001298711-26-000002 · wk-form4_1772580780.xml · nonDerivative · entry 7

Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Spouse

Disclosed balance after: 1,509,075

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · shares: These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Krish S. Krishnan.

F10 · shares: 52,500 PSUs were granted on February 29, 2024, to the Reporting Person's spouse, Krish S. Krishnan. Each PSU represented a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31, 2024, as approved by the Company's Compensation Committee, and the Reporting Person's spouse continued service to the Company on each applicable vesting date following such achievement. The PSUs vested ratably over a two-year period. All of the performance criteria were achieved and the remaining one-half of the PSUs granted, or 26,250 PSUs, vested on February 27, 2026.

F8 · ownership.nature: Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person.

SEC source: 0001298711-26-000002 · wk-form4_1772580780.xml · nonDerivative · entry 6

Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Spouse

Disclosed balance after: 1,482,825

F7 · shares: These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Krish S. Krishnan.

F9 · shares: Represents number of shares of common stock surrendered to the Company for tax withholding by the Reporting Person's spouse, Krish S. Krishnan, upon the vesting of 8,750 RSUs on February 27, 2026.

F3 · price: The closing price on February 27, 2026 of the Company's common stock on the Nasdaq Global Select Market.

F8 · ownership.nature: Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person.

SEC source: 0001298711-26-000002 · wk-form4_1772580780.xml · nonDerivative · entry 5

Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Spouse

Disclosed balance after: 1,486,806

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · shares: 35,000 restricted stock units ("RSUs") were granted on February 29, 2024, to the Reporting Person's spouse, Krish S. Krishnan. Each RSU represents a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's spouse continued service to the Company on each applicable vesting date. The RSUs vest ratably over a four-year period with the second installment, or 8,750 RSUs, vesting on February 27, 2026.

F7 · shares: These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Krish S. Krishnan.

F8 · ownership.nature: Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person.

SEC source: 0001298711-26-000002 · wk-form4_1772580780.xml · nonDerivative · entry 4

Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,428,155

F5 · shares: Represents the number of shares of common stock surrendered to the Company for tax withholding upon the vesting of 4,000 RSUs on February 27, 2026.

F3 · price: The closing price on February 27, 2026 of the Company's common stock on the Nasdaq Global Select Market.

SEC source: 0001298711-26-000002 · wk-form4_1772580780.xml · nonDerivative · entry 3

Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,429,975

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · shares: 16,000 restricted stock units ("RSUs") were granted on February 28, 2025. Each RSU represents a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's continued service to the Company on each applicable vesting date. The RSUs vest ratably over a four-year period with the first installment, or 4,000 RSUs, vesting on February 27, 2026.

SEC source: 0001298711-26-000002 · wk-form4_1772580780.xml · nonDerivative · entry 2

Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,425,975

F2 · shares: Represents the number of shares of common stock surrendered to the Company for tax withholding upon the vesting of 22,500 PSUs on February 27, 2026.

F3 · price: The closing price on February 27, 2026 of the Company's common stock on the Nasdaq Global Select Market.

SEC source: 0001298711-26-000002 · wk-form4_1772580780.xml · nonDerivative · entry 1

Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,436,211

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: 45,000 performance stock units ("PSUs") were granted on February 29, 2024. Each PSU represented a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31, 2024, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement. The PSUs vested ratably over a two-year period. All of the performance criteria were achieved and the remaining one-half of the PSUs granted, or 22,500 PSUs, vested on February 27, 2026.

SEC source: 0001298709-26-000002 · wk-form4_1772580619.xml · derivative · entry 17

Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,140

Underlying: Common Stock · 18,140 shares

Expires not disclosed

F16 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's continued service to the Company on each applicable vesting date.

F17 · shares: The number of RSUs in this column represents the number of shares of common stock the Reporting Person will receive assuming the Reporting Person's continued service to the Company on all applicable vesting dates.

F18 · derivative.exercise_date: The RSUs vest in four equal annual installments with the first installment vesting on February 27, 2027.

F18 · derivative.expiration_date: The RSUs vest in four equal annual installments with the first installment vesting on February 27, 2027.

SEC source: 0001298709-26-000002 · wk-form4_1772580619.xml · derivative · entry 16

Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,249

Underlying: Common Stock · 45,249 shares

Expires 2036-02-26

F15 · derivative.exercise_date: The stock options vests in four equal annual installments beginning on February 27, 2027.

SEC source: 0001298709-26-000002 · wk-form4_1772580619.xml · derivative · entry 15

Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,175

Underlying: Common Stock · 5,725 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_price: 22,900 restricted stock units ("RSUs") were granted on February 28, 2025. Each RSU represents a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's continued service to the Company on each applicable vesting date. The RSUs vest ratably over a four-year period with the first installment, or 5,725 RSUs, vesting on February 27, 2026.

F6 · derivative.exercise_date: 22,900 restricted stock units ("RSUs") were granted on February 28, 2025. Each RSU represents a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's continued service to the Company on each applicable vesting date. The RSUs vest ratably over a four-year period with the first installment, or 5,725 RSUs, vesting on February 27, 2026.

F6 · derivative.expiration_date: 22,900 restricted stock units ("RSUs") were granted on February 28, 2025. Each RSU represents a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's continued service to the Company on each applicable vesting date. The RSUs vest ratably over a four-year period with the first installment, or 5,725 RSUs, vesting on February 27, 2026.

SEC source: 0001298709-26-000002 · wk-form4_1772580619.xml · derivative · entry 14

Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 26,250 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: 52,500 performance stock units ("PSUs") were granted on February 29, 2024. Each PSU represented a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31, 2024, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement. The PSUs vested ratably over a two-year period. All of the performance criteria were achieved and the remaining one-half of the PSUs granted, or 26,250 PSUs, vested on February 27, 2026.

F4 · derivative.exercise_date: 52,500 performance stock units ("PSUs") were granted on February 29, 2024. Each PSU represented a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31, 2024, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement. The PSUs vested ratably over a two-year period. All of the performance criteria were achieved and the remaining one-half of the PSUs granted, or 26,250 PSUs, vested on February 27, 2026.

F4 · derivative.expiration_date: 52,500 performance stock units ("PSUs") were granted on February 29, 2024. Each PSU represented a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31, 2024, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement. The PSUs vested ratably over a two-year period. All of the performance criteria were achieved and the remaining one-half of the PSUs granted, or 26,250 PSUs, vested on February 27, 2026.

SEC source: 0001298709-26-000002 · wk-form4_1772580619.xml · derivative · entry 13

Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,500

Underlying: Common Stock · 8,750 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: 35,000 restricted stock units ("RSUs") were granted on February 29, 2024. Each RSU represents a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's continued service to the Company on each applicable vesting date. The RSUs vest ratably over a four-year period. 8,750 RSUs vested on February 27, 2026.

F1 · derivative.exercise_date: 35,000 restricted stock units ("RSUs") were granted on February 29, 2024. Each RSU represents a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's continued service to the Company on each applicable vesting date. The RSUs vest ratably over a four-year period. 8,750 RSUs vested on February 27, 2026.

F1 · derivative.expiration_date: 35,000 restricted stock units ("RSUs") were granted on February 29, 2024. Each RSU represents a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's continued service to the Company on each applicable vesting date. The RSUs vest ratably over a four-year period. 8,750 RSUs vested on February 27, 2026.

SEC source: 0001298709-26-000002 · wk-form4_1772580619.xml · nonDerivative · entry 10

Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Spouse

Disclosed balance after: 1,428,155

F9 · shares: These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Suma M. Krishnan.

F13 · shares: Represents number of shares of common stock surrendered to the Company for tax withholding by the Reporting Person's spouse, Suma M. Krishnan, upon the vesting of 4,000 RSUs on February 27, 2026.

F3 · price: The closing price on February 27, 2026 of the Company's common stock on the Nasdaq Global Select Market.

F10 · ownership.nature: Directly beneficially owned by Suma M. Krishnan, the spouse of the Reporting Person.

SEC source: 0001298709-26-000002 · wk-form4_1772580619.xml · nonDerivative · entry 9

Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Spouse

Disclosed balance after: 1,429,975

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F9 · shares: These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Suma M. Krishnan.

F12 · shares: 16,000 restricted stock units ("RSUs") were granted on February 28, 2025 to the Reporting Person's spouse, Suma M. Krishnan. Each RSU represents a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's spouse continued service to the Company on each applicable vesting date. The RSUs vest ratably over a four-year period with the first installment, or 4,000 RSUs, vesting on February 27, 2026.

F10 · ownership.nature: Directly beneficially owned by Suma M. Krishnan, the spouse of the Reporting Person.

SEC source: 0001298709-26-000002 · wk-form4_1772580619.xml · nonDerivative · entry 8

Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Spouse

Disclosed balance after: 1,425,975

F9 · shares: These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Suma M. Krishnan.

F11 · shares: Represents number of shares of common stock surrendered to the Company for tax withholding by the Reporting Person's spouse, Suma M. Krishnan, upon the vesting of 22,500 PSUs on February 27, 2026.

F3 · price: The closing price on February 27, 2026 of the Company's common stock on the Nasdaq Global Select Market.

F10 · ownership.nature: Directly beneficially owned by Suma M. Krishnan, the spouse of the Reporting Person.

SEC source: 0001298709-26-000002 · wk-form4_1772580619.xml · nonDerivative · entry 7

Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Spouse

Disclosed balance after: 1,436,211

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · shares: 45,000 performance stock units ("PSUs") were granted on February 29, 2024, to the Reporting Person's spouse, Suma M. Krishnan. Each PSU represented a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31, 2024, as approved by the Company's Compensation Committee, and the Reporting Person's spouse continued service to the Company on each applicable vesting date following such achievement. The PSUs vested ratably over a two-year period. All of the performance criteria were achieved and the remaining one-half of the PSUs granted, or 22,500 PSUs, vested on February 27, 2026.

F9 · shares: These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Suma M. Krishnan.

F10 · ownership.nature: Directly beneficially owned by Suma M. Krishnan, the spouse of the Reporting Person.

SEC source: 0001298709-26-000002 · wk-form4_1772580619.xml · nonDerivative · entry 6

Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,500,253

F7 · shares: Represents the number of shares of common stock surrendered to the Company for tax withholding upon the vesting of 5,725 RSUs on February 27, 2026.

F3 · price: The closing price on February 27, 2026 of the Company's common stock on the Nasdaq Global Select Market.

SEC source: 0001298709-26-000002 · wk-form4_1772580619.xml · nonDerivative · entry 5

Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,502,858

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · shares: 22,900 restricted stock units ("RSUs") were granted on February 28, 2025. Each RSU represents a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's continued service to the Company on each applicable vesting date. The RSUs vest ratably over a four-year period with the first installment, or 5,725 RSUs, vesting on February 27, 2026.

SEC source: 0001298709-26-000002 · wk-form4_1772580619.xml · nonDerivative · entry 4

Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,497,133

F5 · shares: Represents the number of shares of common stock surrendered to the Company for tax withholding upon the vesting of 26,250 PSUs on February 27, 2026.

F3 · price: The closing price on February 27, 2026 of the Company's common stock on the Nasdaq Global Select Market.

SEC source: 0001298709-26-000002 · wk-form4_1772580619.xml · nonDerivative · entry 3

Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,509,075

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · shares: 52,500 performance stock units ("PSUs") were granted on February 29, 2024. Each PSU represented a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31, 2024, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement. The PSUs vested ratably over a two-year period. All of the performance criteria were achieved and the remaining one-half of the PSUs granted, or 26,250 PSUs, vested on February 27, 2026.

SEC source: 0001298709-26-000002 · wk-form4_1772580619.xml · nonDerivative · entry 2

Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,482,825

F2 · shares: Represents the number of shares of common stock surrendered to the Company for tax withholding upon the vesting of 8,750 RSUs on February 27, 2026.

F3 · price: The closing price on February 27, 2026 of the Company's common stock on the Nasdaq Global Select Market.

SEC source: 0001298709-26-000002 · wk-form4_1772580619.xml · nonDerivative · entry 1

Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,486,806

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: 35,000 restricted stock units ("RSUs") were granted on February 29, 2024. Each RSU represents a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's continued service to the Company on each applicable vesting date. The RSUs vest ratably over a four-year period. 8,750 RSUs vested on February 27, 2026.

SEC source: 0001711279-26-000023 · wk-form4_1772580519.xml · nonDerivative · entry 2

JANNEY DANIEL · CIK 0001198325 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · Directly beneficially owned by Alta Bioequities, L.P.

Disclosed balance after: 73,293

F1 · kind: The sale of common stock reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan was entered into on November 25, 2025, and will terminate on November 5, 2026, subject to early termination in accordance with the terms of the Rule 10b5-1 trading plan, including upon completion of the sale of all of the shares of the Company's common stock subject to the Rule 10b5-1 trading plan.

F4 · price: The transaction was executed in multiple trades ranging from $276 to $276.4924. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

F3 · ownership.nature: Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

SEC source: 0001711279-26-000023 · wk-form4_1772580519.xml · nonDerivative · entry 1

JANNEY DANIEL · CIK 0001198325 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · Directly beneficially owned by Alta Bioequities, L.P.

Disclosed balance after: 75,666

F1 · kind: The sale of common stock reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan was entered into on November 25, 2025, and will terminate on November 5, 2026, subject to early termination in accordance with the terms of the Rule 10b5-1 trading plan, including upon completion of the sale of all of the shares of the Company's common stock subject to the Rule 10b5-1 trading plan.

F2 · price: The transaction was executed in multiple trades ranging from $275 to $275.986. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

F3 · ownership.nature: Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

SEC source: 0001711279-26-000021 · wk-form4_1772149785.xml · nonDerivative · entry 21

JANNEY DANIEL · CIK 0001198325 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · Directly beneficially owned by Alta Bioequities, L.P.

Disclosed balance after: 85,096

F11 · kind: The sale of common stock reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan was entered into on November 25, 2025, and will terminate on November 5, 2026, subject to early termination in accordance with the terms of the Rule 10b5-1 trading plan, including upon completion of the sale of all of the shares of the Company's common stock subject to the Rule 10b5-1 trading plan.

F23 · price: The transaction was executed in multiple trades ranging from $276 to $276.99. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

F13 · ownership.nature: Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

SEC source: 0001711279-26-000021 · wk-form4_1772149785.xml · nonDerivative · entry 20

JANNEY DANIEL · CIK 0001198325 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · Directly beneficially owned by Alta Bioequities, L.P.

Disclosed balance after: 87,734

F11 · kind: The sale of common stock reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan was entered into on November 25, 2025, and will terminate on November 5, 2026, subject to early termination in accordance with the terms of the Rule 10b5-1 trading plan, including upon completion of the sale of all of the shares of the Company's common stock subject to the Rule 10b5-1 trading plan.

F22 · price: The transaction was executed in multiple trades ranging from $275 to $275.9782. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

F13 · ownership.nature: Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

SEC source: 0001711279-26-000021 · wk-form4_1772149785.xml · nonDerivative · entry 19

JANNEY DANIEL · CIK 0001198325 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · Directly beneficially owned by Alta Bioequities, L.P.

Disclosed balance after: 92,837

F11 · kind: The sale of common stock reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan was entered into on November 25, 2025, and will terminate on November 5, 2026, subject to early termination in accordance with the terms of the Rule 10b5-1 trading plan, including upon completion of the sale of all of the shares of the Company's common stock subject to the Rule 10b5-1 trading plan.

F21 · price: The transaction was executed in a single trade.

F13 · ownership.nature: Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

SEC source: 0001711279-26-000021 · wk-form4_1772149785.xml · derivative · entry 22

JANNEY DANIEL · CIK 0001198325 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 37,895 shares

Expires 2026-11-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan was entered into on November 25, 2025, and will terminate on November 5, 2026, subject to early termination in accordance with the terms of the Rule 10b5-1 trading plan, including upon completion of the sale of all of the shares of the Company's common stock subject to the Rule 10b5-1 trading plan.

F24 · derivative.exercise_date: The options vested ratably over a four-year period beginning on November 10, 2016.

SEC source: 0001711279-26-000021 · wk-form4_1772149785.xml · nonDerivative · entry 18

JANNEY DANIEL · CIK 0001198325 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · Directly beneficially owned by Alta Bioequities, L.P.

Disclosed balance after: 93,537

F11 · kind: The sale of common stock reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan was entered into on November 25, 2025, and will terminate on November 5, 2026, subject to early termination in accordance with the terms of the Rule 10b5-1 trading plan, including upon completion of the sale of all of the shares of the Company's common stock subject to the Rule 10b5-1 trading plan.

F20 · price: The transaction was executed in multiple trades ranging from $274.59 to $275. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

F13 · ownership.nature: Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

SEC source: 0001711279-26-000021 · wk-form4_1772149785.xml · nonDerivative · entry 17

JANNEY DANIEL · CIK 0001198325 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · Directly beneficially owned by Alta Bioequities, L.P.

Disclosed balance after: 95,962

F11 · kind: The sale of common stock reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan was entered into on November 25, 2025, and will terminate on November 5, 2026, subject to early termination in accordance with the terms of the Rule 10b5-1 trading plan, including upon completion of the sale of all of the shares of the Company's common stock subject to the Rule 10b5-1 trading plan.

F19 · price: The transaction was executed in multiple trades ranging from $269.1641 to $269.78. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

F13 · ownership.nature: Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

SEC source: 0001711279-26-000021 · wk-form4_1772149785.xml · nonDerivative · entry 16

JANNEY DANIEL · CIK 0001198325 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · Directly beneficially owned by Alta Bioequities, L.P.

Disclosed balance after: 96,892

F11 · kind: The sale of common stock reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan was entered into on November 25, 2025, and will terminate on November 5, 2026, subject to early termination in accordance with the terms of the Rule 10b5-1 trading plan, including upon completion of the sale of all of the shares of the Company's common stock subject to the Rule 10b5-1 trading plan.

F18 · price: The transaction was executed in multiple trades ranging from $268.0725 to $269.0705. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

F13 · ownership.nature: Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

SEC source: 0001711279-26-000021 · wk-form4_1772149785.xml · nonDerivative · entry 15

JANNEY DANIEL · CIK 0001198325 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · Directly beneficially owned by Alta Bioequities, L.P.

Disclosed balance after: 98,566

F11 · kind: The sale of common stock reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan was entered into on November 25, 2025, and will terminate on November 5, 2026, subject to early termination in accordance with the terms of the Rule 10b5-1 trading plan, including upon completion of the sale of all of the shares of the Company's common stock subject to the Rule 10b5-1 trading plan.

F17 · price: The transaction was executed in multiple trades ranging from $267.0631 to $268.0275. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

F13 · ownership.nature: Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

SEC source: 0001711279-26-000021 · wk-form4_1772149785.xml · nonDerivative · entry 14

JANNEY DANIEL · CIK 0001198325 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · Directly beneficially owned by Alta Bioequities, L.P.

Disclosed balance after: 100,457

F11 · kind: The sale of common stock reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan was entered into on November 25, 2025, and will terminate on November 5, 2026, subject to early termination in accordance with the terms of the Rule 10b5-1 trading plan, including upon completion of the sale of all of the shares of the Company's common stock subject to the Rule 10b5-1 trading plan.

F16 · price: The transaction was executed in multiple trades ranging from $266.06 to $267.0511. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

F13 · ownership.nature: Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

SEC source: 0001711279-26-000021 · wk-form4_1772149785.xml · nonDerivative · entry 13

JANNEY DANIEL · CIK 0001198325 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · Directly beneficially owned by Alta Bioequities, L.P.

Disclosed balance after: 104,796

F11 · kind: The sale of common stock reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan was entered into on November 25, 2025, and will terminate on November 5, 2026, subject to early termination in accordance with the terms of the Rule 10b5-1 trading plan, including upon completion of the sale of all of the shares of the Company's common stock subject to the Rule 10b5-1 trading plan.

F15 · price: The transaction was executed in multiple trades ranging from $265.04 to $266. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

F13 · ownership.nature: Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

SEC source: 0001711279-26-000021 · wk-form4_1772149785.xml · nonDerivative · entry 12

JANNEY DANIEL · CIK 0001198325 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · Directly beneficially owned by Alta Bioequities, L.P.

Disclosed balance after: 106,400

F11 · kind: The sale of common stock reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan was entered into on November 25, 2025, and will terminate on November 5, 2026, subject to early termination in accordance with the terms of the Rule 10b5-1 trading plan, including upon completion of the sale of all of the shares of the Company's common stock subject to the Rule 10b5-1 trading plan.

F14 · price: The transaction was executed in multiple trades ranging from $264.01 to $264.99. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

F13 · ownership.nature: Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

SEC source: 0001711279-26-000021 · wk-form4_1772149785.xml · nonDerivative · entry 11

JANNEY DANIEL · CIK 0001198325 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · Directly beneficially owned by Alta Bioequities, L.P.

Disclosed balance after: 107,300

F11 · kind: The sale of common stock reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan was entered into on November 25, 2025, and will terminate on November 5, 2026, subject to early termination in accordance with the terms of the Rule 10b5-1 trading plan, including upon completion of the sale of all of the shares of the Company's common stock subject to the Rule 10b5-1 trading plan.

F12 · price: The transaction was executed in multiple trades ranging from $262.9496 to $263.1269. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

F13 · ownership.nature: Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

SEC source: 0001711279-26-000021 · wk-form4_1772149785.xml · nonDerivative · entry 10

JANNEY DANIEL · CIK 0001198325 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F10 · price: The transaction was executed in multiple trades ranging from $270.650 to $271.610. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

SEC source: 0001711279-26-000021 · wk-form4_1772149785.xml · nonDerivative · entry 9

JANNEY DANIEL · CIK 0001198325 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 373

F9 · price: The transaction was executed in multiple trades ranging from $269.610 to $270.140. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

SEC source: 0001711279-26-000021 · wk-form4_1772149785.xml · nonDerivative · entry 8

JANNEY DANIEL · CIK 0001198325 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 743

F8 · price: The transaction was executed in multiple trades ranging from $268.540 to $269.530. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

SEC source: 0001711279-26-000021 · wk-form4_1772149785.xml · nonDerivative · entry 7

JANNEY DANIEL · CIK 0001198325 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,706

F7 · price: The transaction was executed in multiple trades ranging from $267.520 to $268.510. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.